ResearcherFujian Medical UniversityActive in the last 2 years

Shengzhe Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-2520-8957; OpenAlex author ID A5005487456. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 1 paper

Papers 2

BCL2A1 neoepitope-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer. Co-author DOI 10.1093/jleuko/qiae092 ↗
Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer. Co-author DOI 10.1002/jlb.5ma0922-749r ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jingwen Hong · 2 shared papers, 2022–2024 · strength 0.37
- Paper BCL2A1 neoepitope-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer. DOI 10.1093/jleuko/qiae092 ↗
- Paper Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer. DOI 10.1002/jlb.5ma0922-749r ↗
Yunbin Ye · 2 shared papers, 2022–2024 · strength 0.37
- Paper BCL2A1 neoepitope-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer. DOI 10.1093/jleuko/qiae092 ↗
- Paper Altered MUC1 epitope-specific CTLs: A potential target for immunotherapy of pancreatic cancer. DOI 10.1002/jlb.5ma0922-749r ↗
Yanling Chen · 1 shared paper, 2024 · strength 0.22
- Paper BCL2A1 neoepitope-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer. DOI 10.1093/jleuko/qiae092 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.